Page last updated: 2024-08-24

thiazolyl blue and Sarcoma

thiazolyl blue has been researched along with Sarcoma in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chao, R; Chen, H; Chen, Q; Hou, X; Peng, W; Xu, A; Yan, H; Zhou, S	1
Freedman, MH; Ganjavi, H; Gee, M; Malkin, D; Narendran, A	1

Other Studies

2 other study(ies) available for thiazolyl blue and Sarcoma

Article	Year
Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis. International journal of cancer, 2005, May-01, Volume: 114, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Lewis Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Coloring Agents; DNA; fas Receptor; Flow Cytometry; Harmine; Humans; Immunoblotting; Inhibitory Concentration 50; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Models, Chemical; Monoamine Oxidase Inhibitors; Neoplasm Transplantation; Peganum; Proto-Oncogene Proteins c-bcl-2; Sarcoma; Structure-Activity Relationship; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Suppressor Protein p53; Up-Regulation	2005
Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer gene therapy, 2005, Volume: 12, Issue:4 Topics: Adenoviridae; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Doxorubicin; Gene Transfer Techniques; Genes, p53; Genetic Therapy; Humans; In Situ Nick-End Labeling; Mutation; Prognosis; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma; RNA, Messenger; Sarcoma; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Suppressor Protein p53	2005

Article

Year

Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis.

International journal of cancer, 2005, May-01, Volume: 114, Issue:5

Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Lewis Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Coloring Agents; DNA; fas Receptor; Flow Cytometry; Harmine; Humans; Immunoblotting; Inhibitory Concentration 50; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Models, Chemical; Monoamine Oxidase Inhibitors; Neoplasm Transplantation; Peganum; Proto-Oncogene Proteins c-bcl-2; Sarcoma; Structure-Activity Relationship; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Suppressor Protein p53; Up-Regulation

2005

Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.

Cancer gene therapy, 2005, Volume: 12, Issue:4

Topics: Adenoviridae; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Doxorubicin; Gene Transfer Techniques; Genes, p53; Genetic Therapy; Humans; In Situ Nick-End Labeling; Mutation; Prognosis; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma; RNA, Messenger; Sarcoma; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Suppressor Protein p53

2005